Fundz

Fundz Deep Dive

Everything you need to win Oncomatryx Biopharma — in one platform.

Who to reach, what to say, and why now on Oncomatryx Biopharma — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Oncomatryx Biopharma — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Oncomatryx Biopharma has been awarded €12.5 million in EIC Accelerator funding to advance groundbreaking ADCs for oncology. This funding includes €2.5 million in grants and €10 million in equity investment.

PRIVATEJul 15, 2025•11 months ago

Amount Raised

€12.5 Million

Autonomous Community Of The Basque CountryBiotechnologyHealth CareTherapeutics

Description

Oncomatryx Biopharma, a biotechnology company specializing in Antibody-Drug Conjugates (ADCs) for oncology, received €12.5 million in EIC Accelerator funding. This funding, part of the EU's Horizon Europe program, includes €2.5 million in grants and €10 million in equity investment. A total of 40 companies were selected from 959 applications. This funding will help advance their Phase I clinical trial for difficult-to-treat cancers.

Company Information

Company

Oncomatryx Biopharma

Location

Autonomous Community Of The Basque Country, Spain

About

Oncomatryx Biopharma is a biotechnology company pioneering next-generation Antibody-Drug Conjugates (ADCs) for oncology. The company's unique ADC platform integrates proprietary novel payloads and advanced conjugation formats, supporting innovative drug development. With a focus on treating hard-to-treat solid tumors, Oncomatryx is recognized as a strategic leader in oncology innovation. The company is advancing its lead ADC candidate, OMTX705, targeting aggressive tumors with high unmet medical needs.

Related People

Suggested for you
2 contacts

Choose your plan to reveal verified contacts

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Oncomatryx Biopharma's next move

Learn about Strategic plan

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.

Watching Oncomatryx Biopharma? See every signal — funding, hires, M&A, contracts, sentiment.

Request a demoChoose your plan